Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma

about

Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma

Item

http://www.wikidata.org/entity/Q58766967

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Response to pembrolizumab in a ...... astatic ovarian carcinosarcoma

@en

Response to pembrolizumab in a ...... astatic ovarian carcinosarcoma

@nl

type

Item

label

Response to pembrolizumab in a ...... astatic ovarian carcinosarcoma

@en

Response to pembrolizumab in a ...... astatic ovarian carcinosarcoma

@nl

prefLabel

Response to pembrolizumab in a ...... astatic ovarian carcinosarcoma

@en

Response to pembrolizumab in a ...... astatic ovarian carcinosarcoma

@nl

P1476

Response to pembrolizumab in a ...... astatic ovarian carcinosarcoma

@en

P2093

Carina Meira Abrahão

http://www.w3.org/2001/XMLSchema#string

Fernando Cotait Maluf

http://www.w3.org/2001/XMLSchema#string

Graziela Zibetti Dal Molin

http://www.w3.org/2001/XMLSchema#string

Robert L Coleman

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma

Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?

Carcinosarcoma of the ovary: 19 years of prospective data from a single center.

Immune checkpoint inhibitors in clinical trials

Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.

Pathology of mixed Müllerian tumours.

Carcinosarcoma of the ovary: a review of the literature.

Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.

P2888

s40661-018-0063-3

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1186/S40661-018-0063-3

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1106227207

http://www.w3.org/2001/XMLSchema#string

P698

30147940

http://www.w3.org/2001/XMLSchema#string

P932

6098839

http://www.w3.org/2001/XMLSchema#string